NY-BCW
10.7.2019 19:34:12 CEST | Business Wire | Press release
BCW (Burson Cohn & Wolfe), a leading global communications agency, announced today that Ben Boyd will join the agency as Global Chief Strategy and Operations Officer, effective September 3, 2019. Boyd will partner with BCW’s Global CEO Donna Imperato across all five of the agency’s global regions on strategy, operations and client development. He will also manage critical client relationships, help develop new business and advise on intellectual property development. Boyd will become a member of BCW’s board of directors and be based in New York.
“Ben is an extraordinary talent whose hands-on counsel has been sought after by many of the world’s largest and most powerful brands and organizations thanks to his deep expertise across earned media, thought leadership and integrated communications,” said Imperato. “He is also renowned for creating and operationalizing a client-centric workplace, which will make him an invaluable partner for BCW’s continued growth.
“This is an incredibly exciting time for BCW,” Imperato added. “We now have our global senior leadership team fully in place, our business is growing and we are nurturing a culture where our people, and therefore our clients, thrive. I am thrilled to welcome a leader of Ben’s caliber to our team and to partner with him in further establishing BCW as an unstoppable force in moving people to drive business transformation and meaningful results.”
Boyd spent the past 14 years with Edelman, most recently as Chief Client Strategy Officer overseeing the agency’s client experience program, counseling C-suite executives and partnering with the firm’s top clients. He also led Edelman’s signature intellectual property studies, including The Trust Barometer. Before that, he spent 11 years at the helm of Edelman’s Global Corporate Practice, overseeing Global Practices and Sectors, managing the firm’s global marketing function and leading key clients.
Prior to Edelman, he was Assistant to the President, Director of Communications at the Service Employees International Union (SEIU), where he managed the national communications campaign for a newly relevant labor movement and oversaw SEIU’s earned, paid, social and new media strategies nationally. Previously, he served as Director of Communications for SITA, one of the world’s largest providers of IT resources for the air transport industry. Before that, he was Vice President of Marketing and Communications for barnesandnoble.com, launching the site and taking the company through an initial public offering. Earlier in his career, he held senior roles at Weber Shandwick and Hill & Knowlton (now H+K Strategies).
“I am profoundly honored to join BCW at this critical juncture in its growth and ambition to define our industry,” said Boyd. “As the lines continue to blur across the entire marketing communications spectrum, the industry needs clear leadership and champions for the value of earned media as both the starting point and the core of integrated communications programs that truly make an impact on a client’s business. BCW has the offerings, the values and the vision to be that beacon. I am incredibly inspired by BCW’s team and culture and am excited for what we will achieve.”
Boyd is currently a member of the Business Advisory Council of ProPublica (2011 to present) and had been a Member of the National Board of Directors of The Trevor Project (2014 to 2017).
About BCW
BCW (Burson Cohn & Wolfe), one of the world’s largest full-service global communications agencies, is in the business of moving people on behalf of clients. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE: WPP), a creative transformation company. For more information, visit www.bcw-global.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom